Mediators of Inflammation / 2013 / Article / Fig 4

Research Article

Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 4

Luxol fast blue staining and MBP immunostaining for spinal cord and cerebral cortex. ((a)–(h)) C16 treatment prevented demyelination in spinal cord and cerebral cortex both at weeks 2 and 8 after immunization; Luxol fast blue staining; traverse section through the lumbar spinal cord; bar = 100 μm. At week 2 after immunization, normal rats (a), vehicle control rats (b) (inserted image depicting the inflammatory cells infiltrated demyelination area in anterior funiculus), 2 mg/per day C16 treated EAE rats (c) and C16 late treated EAE rats (d). At week 8 after immunization, vehicle control rats (e), 0.5 mg (f) and 2 mg (g)/day C16 treated EAE rats, and C16 late treated EAE rats (h). ((i)–(p)) C16 treatment prevented demyelination in spinal cord and cerebral cortex both at weeks 2 and 8 after immunization, MBP immunostaining, counterstained with hematoxylin ((i), (k), (m), and (o) coronal sections of motor cortex; (j), (l), (n), and (p) traverse sections through the lumbar spinal cord). At week 2 after immunization, normal rats ((i), (j)), vehicle control rats ((k), (l)), 2 mg/per day C16 treated EAE rats ((m), (n)) and C16 late treated EAE rats ((o), (p)).
268486.fig.004a
(a)
268486.fig.004b
(b)
268486.fig.004c
(c)
268486.fig.004d
(d)
268486.fig.004e
(e)
268486.fig.004f
(f)
268486.fig.004g
(g)
268486.fig.004h
(h)
268486.fig.004i
(i)
268486.fig.004j
(j)
268486.fig.004k
(k)
268486.fig.004l
(l)
268486.fig.004m
(m)
268486.fig.004n
(n)
268486.fig.004o
(o)
268486.fig.004p
(p)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.